Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued.

Gene-editing pioneer CRISPR Therapeutics (CRSP 1.22%) stands out in this regard. Despite serious doubt from many in the scientific community, the biotech successfully advanced its gene-edited therapy Casgevy through clinical trials and subsequently won regulatory approvals in several territories such as the U.S., U.K., the European Union, and the Kingdom of Saudi Arabia for both sickle cell disease (SCD) and transfusiondependent beta-thalassemia (TDT). Morningstar analyst Rachel Elfman recently placed a $11 ...